PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
38.10%
Revenue growth 1.25-1.5x 6617.T's 31.41%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-1.49%
Negative gross profit growth while 6617.T is at 2.10%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.17%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-24.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-27.98%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-28.02%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-28.02%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.38%
OCF growth above 1.5x 6617.T's 4.78%. David Dodd would confirm a clear edge in underlying cash generation.
14.38%
FCF growth above 1.5x 6617.T's 4.78%. David Dodd would verify if the firm’s strategic investments yield superior returns.
67.46%
10Y revenue/share CAGR above 1.5x 6617.T's 8.67%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-49.63%
Negative 5Y CAGR while 6617.T stands at 9.58%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.53%
Negative 3Y CAGR while 6617.T stands at 5.80%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.05%
Negative 10Y net income/share CAGR while 6617.T is at 135.25%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-84.89%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-74.03%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
107.45%
10Y equity/share CAGR above 1.5x 6617.T's 15.49%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
29.24%
5Y equity/share CAGR above 1.5x 6617.T's 11.34%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
21.55%
3Y equity/share CAGR above 1.5x 6617.T's 12.98%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.74%
Firm’s AR is declining while 6617.T shows 18.56%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-21.30%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-7.12%
Negative asset growth while 6617.T invests at 4.56%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.72%
1.25-1.5x 6617.T's 1.25%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-11.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-11.76%
Our R&D shrinks while 6617.T invests at 14.25%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
9.10%
SG&A growth well above 6617.T's 11.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.